Trials / Withdrawn
WithdrawnNCT04891497
Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimethyl Fumarate | Dimethyl fumarate 240mg orally twice daily for 3 consecutive days |
| DRUG | Placebo | Placebo 240mg orally twice daily for 3 consecutive days |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-05-18
- Last updated
- 2023-10-25
Source: ClinicalTrials.gov record NCT04891497. Inclusion in this directory is not an endorsement.